n hESC translation and commercialisation. However, the regenerative medicine sector has been able to recover and is beginning to blossom. (See Public Markets section below). The prime movers in the Geron trial are now attempting to revive it. Research funding robust Federal funding for all forms of stem

vs. 300% threshold). That said, management remains selective and has implemented a 25-30% concentration limit (3Q: 22%). Citigroup (C), B-1-7, Buy Markets revenue up YoY so far, down from robust 3Q. President and CEO of ICG Jamie Forese and CFO John Gerspach noted that at this current point in time, the